Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma

Kouji Tanaka, Akira Ito, Takeshi Kobayashi, Tatsuyoshi Kawamura, Shinji Shimada, Kazuhiko Matsumoto, Toshiaki Saida, Hiroyuki Honda

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that play important roles in regulating immune responses in cancer. Immunotherapy using these immunocytes has become an accepted therapeutic modality. We previously reported that hyperthermia using magnetic nanoparticles induces antitumor immunity, which could be activated by adjuvant including cytokines. In the present study, we investigated the therapeutic effects of hyperthermia combined with DC immunotherapy on mouse EL4 T-lymphoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into an EL4 nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the surface of the tumor reached 450C and was maintained by controlling the magnetic field intensity. Hyperthermia treatment was repeated twice with 24 h intervals. After hyperthermia, immature DCs were directly injected into the EL4 nodule. As a result, complete regression of tumors in 75% (6/8) of the mice was observed, while the percentage of complete regression of tumors was 12.5% (1/8) in the case of mice treated by hyperthermia alone. This novel cancer therapy, which we have termed "heat immunotherapy", may be applicable to patients with advanced malignancies.

Original languageEnglish
Pages (from-to)112-115
Number of pages4
JournalJournal of Bioscience and Bioengineering
Volume100
Issue number1
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Immunotherapy
Nanoparticles
Dendritic Cells
Ferrosoferric Oxide
Tumors
Lymphoma
Liposomes
Hot Temperature
Magnetite
Magnetic fields
Fever
Magnetic Fields
Neoplasms
Surface charge
Hysteresis
Cytokines
Induced Hyperthermia
Therapeutic Uses
Antigen-Presenting Cells
Inbred C57BL Mouse

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Tanaka, K., Ito, A., Kobayashi, T., Kawamura, T., Shimada, S., Matsumoto, K., ... Honda, H. (2005). Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. Journal of Bioscience and Bioengineering, 100(1), 112-115. https://doi.org/10.1263/jbb.100.112

Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. / Tanaka, Kouji; Ito, Akira; Kobayashi, Takeshi; Kawamura, Tatsuyoshi; Shimada, Shinji; Matsumoto, Kazuhiko; Saida, Toshiaki; Honda, Hiroyuki.

In: Journal of Bioscience and Bioengineering, Vol. 100, No. 1, 01.01.2005, p. 112-115.

Research output: Contribution to journalArticle

Tanaka, K, Ito, A, Kobayashi, T, Kawamura, T, Shimada, S, Matsumoto, K, Saida, T & Honda, H 2005, 'Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma', Journal of Bioscience and Bioengineering, vol. 100, no. 1, pp. 112-115. https://doi.org/10.1263/jbb.100.112
Tanaka, Kouji ; Ito, Akira ; Kobayashi, Takeshi ; Kawamura, Tatsuyoshi ; Shimada, Shinji ; Matsumoto, Kazuhiko ; Saida, Toshiaki ; Honda, Hiroyuki. / Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. In: Journal of Bioscience and Bioengineering. 2005 ; Vol. 100, No. 1. pp. 112-115.
@article{4310b4f0de1942699470e33defa72a3d,
title = "Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma",
abstract = "Dendritic cells (DCs) are potent antigen-presenting cells that play important roles in regulating immune responses in cancer. Immunotherapy using these immunocytes has become an accepted therapeutic modality. We previously reported that hyperthermia using magnetic nanoparticles induces antitumor immunity, which could be activated by adjuvant including cytokines. In the present study, we investigated the therapeutic effects of hyperthermia combined with DC immunotherapy on mouse EL4 T-lymphoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into an EL4 nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the surface of the tumor reached 450C and was maintained by controlling the magnetic field intensity. Hyperthermia treatment was repeated twice with 24 h intervals. After hyperthermia, immature DCs were directly injected into the EL4 nodule. As a result, complete regression of tumors in 75{\%} (6/8) of the mice was observed, while the percentage of complete regression of tumors was 12.5{\%} (1/8) in the case of mice treated by hyperthermia alone. This novel cancer therapy, which we have termed {"}heat immunotherapy{"}, may be applicable to patients with advanced malignancies.",
author = "Kouji Tanaka and Akira Ito and Takeshi Kobayashi and Tatsuyoshi Kawamura and Shinji Shimada and Kazuhiko Matsumoto and Toshiaki Saida and Hiroyuki Honda",
year = "2005",
month = "1",
day = "1",
doi = "10.1263/jbb.100.112",
language = "English",
volume = "100",
pages = "112--115",
journal = "Journal of Bioscience and Bioengineering",
issn = "1389-1723",
publisher = "The Society for Biotechnology, Japan",
number = "1",

}

TY - JOUR

T1 - Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma

AU - Tanaka, Kouji

AU - Ito, Akira

AU - Kobayashi, Takeshi

AU - Kawamura, Tatsuyoshi

AU - Shimada, Shinji

AU - Matsumoto, Kazuhiko

AU - Saida, Toshiaki

AU - Honda, Hiroyuki

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Dendritic cells (DCs) are potent antigen-presenting cells that play important roles in regulating immune responses in cancer. Immunotherapy using these immunocytes has become an accepted therapeutic modality. We previously reported that hyperthermia using magnetic nanoparticles induces antitumor immunity, which could be activated by adjuvant including cytokines. In the present study, we investigated the therapeutic effects of hyperthermia combined with DC immunotherapy on mouse EL4 T-lymphoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into an EL4 nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the surface of the tumor reached 450C and was maintained by controlling the magnetic field intensity. Hyperthermia treatment was repeated twice with 24 h intervals. After hyperthermia, immature DCs were directly injected into the EL4 nodule. As a result, complete regression of tumors in 75% (6/8) of the mice was observed, while the percentage of complete regression of tumors was 12.5% (1/8) in the case of mice treated by hyperthermia alone. This novel cancer therapy, which we have termed "heat immunotherapy", may be applicable to patients with advanced malignancies.

AB - Dendritic cells (DCs) are potent antigen-presenting cells that play important roles in regulating immune responses in cancer. Immunotherapy using these immunocytes has become an accepted therapeutic modality. We previously reported that hyperthermia using magnetic nanoparticles induces antitumor immunity, which could be activated by adjuvant including cytokines. In the present study, we investigated the therapeutic effects of hyperthermia combined with DC immunotherapy on mouse EL4 T-lymphoma. Magnetite cationic liposomes (MCLs) have a positive surface charge and generate heat in an alternating magnetic field (AMF) due to hysteresis loss. MCLs were injected into an EL4 nodule in C57BL/6 mice, which were subjected to AMF for 30 min. The temperature at the surface of the tumor reached 450C and was maintained by controlling the magnetic field intensity. Hyperthermia treatment was repeated twice with 24 h intervals. After hyperthermia, immature DCs were directly injected into the EL4 nodule. As a result, complete regression of tumors in 75% (6/8) of the mice was observed, while the percentage of complete regression of tumors was 12.5% (1/8) in the case of mice treated by hyperthermia alone. This novel cancer therapy, which we have termed "heat immunotherapy", may be applicable to patients with advanced malignancies.

UR - http://www.scopus.com/inward/record.url?scp=27644578566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644578566&partnerID=8YFLogxK

U2 - 10.1263/jbb.100.112

DO - 10.1263/jbb.100.112

M3 - Article

C2 - 16233860

AN - SCOPUS:27644578566

VL - 100

SP - 112

EP - 115

JO - Journal of Bioscience and Bioengineering

JF - Journal of Bioscience and Bioengineering

SN - 1389-1723

IS - 1

ER -